1. Introduction to Batch Packing Record (BPR) of Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP:
The Batch Packing Record (BPR) of Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP is an essential pharmaceutical document designed to ensure systematic documentation, traceability, and compliance with Good Manufacturing Practices (GMP) during pharmaceutical packaging operations. Each uncoated tablet contains Paracetamol IP 325 mg, Phenylephrine Hydrochloride IP 5 mg, Chlorpheniramine Maleate IP 2 mg, and Caffeine Anhydrous IP 30 mg. This combination is formulated for symptomatic relief of common cold symptoms, including fever, headache, nasal congestion, and allergic manifestations. The BPR provides comprehensive documentation of packaging material dispensing, line clearance, machine setup, blister packaging, overprinting verification, in-process quality checks, and finished product reconciliation. It includes essential parameters such as sealing temperature, forming temperature, machine speed, leak testing, environmental conditions, packaging quantities, and material accountability. Additionally, the record facilitates monitoring of packaging defects, rejection analysis, yield calculations, material destruction, and finished goods transfer. Proper documentation supports batch traceability, prevention of product mix-ups, and compliance with established quality standards. The BPR ensures that packaging activities are performed according to approved procedures, verified by authorized personnel, and reviewed by Quality Assurance before final batch release, supporting consistent pharmaceutical product quality, integrity, and patient safety throughout the packaging process.
Skip to PDF content1. Flow Diagram Description of Batch Packing Process for Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP:
The flow diagram of the Batch Packing Record (BPR) for Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP illustrates the systematic sequence of pharmaceutical packaging operations performed under Good Manufacturing Practices (GMP). The process begins with the receipt and verification of approved bulk tablets from the manufacturing department. Packaging materials, including blister foil, PVC film, printed labels, and shippers, are dispensed and verified against approved specifications. Following packaging material verification, line clearance and machine setup are performed to ensure the packaging area is clean and free from previous product materials. Blister packaging operations involve forming, tablet feeding, sealing, and cutting under controlled operating conditions.

In-process quality control checks include blister integrity, leak testing, sealing quality, overprinting accuracy, tablet count, and packaging appearance. Defective packaging materials and rejected products are segregated and documented.The accepted blister packs undergo secondary packaging, labeling, overprinting verification, and final inspection. Packaging material reconciliation, rejection analysis, and yield calculations are completed to ensure material accountability. Finally, packed products are transferred to the finished goods store with appropriate documentation. The completed BPR undergoes Quality Assurance review and approval before batch release, ensuring product quality, traceability, regulatory compliance, and patient safety.
2. Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP:
The Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate & Caffeine Anhydrous Tablets IP play an essential role in maintaining pharmaceutical product quality, safety, efficacy, and regulatory compliance throughout manufacturing and packaging operations.

Critical Process Parameters (CPP) are operating conditions whose variability may significantly affect product quality. During blister packaging, important process parameters include forming temperature, sealing temperature, sealing pressure, machine speed, blister forming depth, and packaging material specifications. Proper control of these parameters ensures consistent blister formation, effective sealing, and protection against environmental factors. Additional packaging controls include line clearance, tablet feeding accuracy, overprinting verification, leak testing, and periodic in-process inspections to prevent contamination, product mix-ups, and packaging defects.
Critical Quality Attributes (CQA) represent measurable physical, chemical, and packaging characteristics necessary to maintain the required product quality. These include tablet appearance, identification, assay, content uniformity, dissolution, disintegration, blister integrity, packaging accuracy, and labeling correctness. Effective monitoring of CPPs helps maintain CQAs within approved specifications. The Batch Packing Record (BPR) documents critical packaging activities, inspection results, deviations, rejection analysis, and material reconciliation. Systematic evaluation and control of CPPs and CQAs support consistent product quality, GMP compliance, batch traceability, and patient safety.
Note: Specific CPP classifications, operating limits, and CQA acceptance criteria must be established through approved process validation, packaging qualification, and product specifications.





